---
title: "Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300445660.md"
description: "Gymnast Simone Biles partners with Arcutis to launch the 'Skin to Believe In' campaign, raising awareness for seborrheic dermatitis and eczema. Aiming to educate millions affected by these conditions, the initiative empowers patients with resources and support for effective management."
datetime: "2026-09-29T13:19:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300445660.md)
  - [en](https://longbridge.com/en/news/300445660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300445660.md)
generator: "portal-rs"
---

# Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options

Renowned gymnast Simone Biles has collaborated with Arcutis to introduce the Skin to Believe In Campaign. This initiative aims to bring attention to Seborrheic Dermatitis and Eczema, common skin conditions affecting millions worldwide. By teaming up with Biles, the campaign hopes to reach a wider audience and educate about these conditions. Seborrheic Dermatitis impacts roughly 11 million individuals in the United States alone, while Eczema affects over 31 million. The partnership between Biles and Arcutis seeks to empower those facing these skin issues and provide support and resources for managing them effectively.

### Related Stocks

- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)

## Related News & Research

- [Arcutis Biotherapeutics Director Howard G. Welgus Reports Disposal of Common Shares Worth $127,325.04](https://longbridge.com/en/news/302327833.md)
- [Cantor Fitzgerald initiates coverage of Arcutis Biotherapeutics with Overweight rating, $48 price target](https://longbridge.com/en/news/301963556.md)
- [Arcutis says Phase 2 trial shows Zoryve cream 0.05% clears atopic dermatitis in infants ages 3 to under 24 months](https://longbridge.com/en/news/301396737.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.](https://longbridge.com/en/news/302948213.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**